Literature DB >> 14645482

Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations.

Julianne A Lombardo1, Edward A Stern, Megan E McLellan, Stephen T Kajdasz, Gregory A Hickey, Brian J Bacskai, Bradley T Hyman.   

Abstract

The accumulation of amyloid-beta into insoluble plaques is a characteristic feature of Alzheimer's disease. Neuronal morphology is distorted by plaques: rather than being essentially straight, they are substantially more curved than those in control tissue, their trajectories become altered, and they are frequently distended or swollen, presumably affecting synaptic transmission. Clearance of plaques by administration of antibodies to amyloid-beta is a promising therapeutic approach to the treatment of Alzheimer's disease, leading to stabilization of dementia by an unknown cellular mechanism. The effect of plaque clearance on plaque-induced neuronal alterations has not been studied previously. Here we show that both plaques and neuritic lesions are reversible in a strikingly short period of time after administration of a single dose of amyloid-beta antibody. Amyloid clearance and recovery of normal neuronal geometries were observed as early as 4 d and lasted at least 32 d after a single treatment. These results demonstrate that, once plaques are cleared, neuronal morphology is self-correcting and that passive antibody treatment has the potential to reverse neuronal damage caused by Alzheimer's disease and, hence, directly impact cognitive decline. Moreover, the rapid normalization of neuritic dystrophy suggests an unexpected degree of plasticity in the adult nervous system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645482      PMCID: PMC6740984     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  67 in total

1.  Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.

Authors:  B DaRocha-Souto; M Coma; B G Pérez-Nievas; T C Scotton; M Siao; P Sánchez-Ferrer; T Hashimoto; Z Fan; E Hudry; I Barroeta; L Serenó; M Rodríguez; M B Sánchez; B T Hyman; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

Review 2.  Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse models.

Authors:  Jennifer I Luebke; Christina M Weaver; Anne B Rocher; Alfredo Rodriguez; Johanna L Crimins; Dara L Dickstein; Susan L Wearne; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2010-02-24       Impact factor: 3.270

3.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.

Authors:  Bing Gong; Ottavio V Vitolo; Fabrizio Trinchese; Shumin Liu; Michael Shelanski; Ottavio Arancio
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

4.  Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model.

Authors:  Tara L Spires-Jones; Melanie Meyer-Luehmann; Jennifer D Osetek; Phillip B Jones; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

5.  Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Authors:  Sylvia E Perez; Bin He; Muhammad Nadeem; Joanne Wuu; Stephen W Scheff; Eric E Abrahamson; Milos D Ikonomovic; Elliott J Mufson
Journal:  Biol Psychiatry       Date:  2014-01-11       Impact factor: 13.382

6.  Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy.

Authors:  Tara L Spires; Melanie Meyer-Luehmann; Edward A Stern; Pamela J McLean; Jesse Skoch; Paul T Nguyen; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2005-08-03       Impact factor: 6.167

7.  Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease.

Authors:  Jennifer B Paulson; Martin Ramsden; Colleen Forster; Mathew A Sherman; Eileen McGowan; Karen H Ashe
Journal:  Am J Pathol       Date:  2008-07-31       Impact factor: 4.307

8.  Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance.

Authors:  Thierry Bussière; Frédérique Bard; Robin Barbour; Henry Grajeda; Terry Guido; Karen Khan; Dale Schenk; Dora Games; Peter Seubert; Manuel Buttini
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 9.  Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity.

Authors:  Levi M Smith; Stephen M Strittmatter
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

Review 10.  Immunotherapy for Alzheimer's disease.

Authors:  David S Gelinas; Kevin DaSilva; Daniela Fenili; Peter St George-Hyslop; Joanne McLaurin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.